Racial disparities in BRCA testing and cancer risk management across a population-based sample of young breast cancer survivors

Cancer

Volumn 123, Issue 13, 2017, Pages 2497-2505

  Cragun, Deborah ^a,b   Weidner, Anne ^a   Lewis, Courtney ^a   Bonner, Devon ^a   Kim, Jongphil ^a   Vadaparampil, Susan T ^a   Pal, Tuya ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

breast cancer; cancer disparities; cancer risk management genetic testing; hereditary cancer

Indexed keywords

BRCA1 PROTEIN; EPIDERMAL GROWTH FACTOR RECEPTOR; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR;

ARTICLE; BLACK PERSON; BREAST CANCER; CANCER REGISTRY; CANCER RISK; CANCER SCREENING; CANCER SURVIVOR; COMMUNITY CARE; CONTROLLED STUDY; ETHNIC DIFFERENCE; FAMILY HISTORY; FEMALE; GENE MUTATION; GENETIC SCREENING; HISPANIC; HUMAN; MAJOR CLINICAL STUDY; MASTECTOMY; POPULATION RESEARCH; PRIORITY JOURNAL; PRIVATE HEALTH INSURANCE; RACE DIFFERENCE; RACISM; RISK MANAGEMENT; SALPINGOOOPHORECTOMY; SOCIOECONOMICS; TRIPLE NEGATIVE BREAST CANCER; TUMOR SUPPRESSOR GENE; ADULT; AFRICAN AMERICAN; BREAST NEOPLASMS; CAUCASIAN; ETHNIC GROUP; ETHNOLOGY; GENETICS; HEALTH CARE DISPARITY; HEREDITARY BREAST AND OVARIAN CANCER SYNDROME; HETEROZYGOTE; MIDDLE AGED; MULTIVARIATE ANALYSIS; OVARIAN NEOPLASMS; OVARIECTOMY; PROPHYLACTIC MASTECTOMY; PROPHYLACTIC SURGICAL PROCEDURE; RISK ASSESSMENT; SALPINGECTOMY; STATISTICAL MODEL; STATISTICS AND NUMERICAL DATA; SURVIVOR; UTILIZATION;

ADULT; AFRICAN AMERICANS; BREAST NEOPLASMS; ETHNIC GROUPS; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENES, BRCA1; GENES, BRCA2; GENETIC TESTING; HEALTHCARE DISPARITIES; HEREDITARY BREAST AND OVARIAN CANCER SYNDROME; HETEROZYGOTE; HISPANIC AMERICANS; HUMANS; LOGISTIC MODELS; MIDDLE AGED; MULTIVARIATE ANALYSIS; OVARIAN NEOPLASMS; OVARIECTOMY; PROPHYLACTIC MASTECTOMY; PROPHYLACTIC SURGICAL PROCEDURES; RISK ASSESSMENT; SALPINGECTOMY; SURVIVORS;

EID: 85013459725     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.30621     Document Type: Article

References (53)

1. Miki Y, Swensen J, Shattuck-Eidens D, et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science. 1994;266:66-71.
2. Wooster R, Bignell G, Lancaster J, et al. Identification of the breast cancer susceptibility gene BRCA2. Nature. 1995;378:789-792.
3. Antoniou A, Pharoah PD, Narod S, et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet. 2003;72:1117-1130.
4. Litton JK, Ready K, Chen H, et al. Earlier age of onset of BRCA mutation-related cancers in subsequent generations. Cancer. 2012;118:321-325.
5. Chen S, Parmigiani G. Meta-analysis of BRCA1 and BRCA2 penetrance. J Clin Oncol. 2007;25:1329-1333.
6. King MC, Marks JH, Mandell JB. Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science. 2003;302:643-646.
7. Graeser MK, Engel C, Rhiem K, et al. Contralateral breast cancer risk in BRCA1 and BRCA2 mutation carriers. J Clin Oncol. 2009;27:5887-5892.
8. Malone KE, Begg CB, Haile RW, et al. Population-based study of the risk of second primary contralateral breast cancer associated with carrying a mutation in BRCA1 or BRCA2. J Clin Oncol. 2010;28:2404-2410.
9. Domchek SM, Friebel TM, Singer CF, et al. Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. JAMA. 2010;304:967-975.
10. Finch AP, Lubinski J, Moller P, et al. Impact of oophorectomy on cancer incidence and mortality in women with a BRCA1 or BRCA2 mutation. J Clin Oncol. 2014;32:1547-1553.
11. National Comprehensive Cancer Network (NCCN). Genetic/familial high-risk assessment: breast and ovarian. Available at: http://www.nccn.org/professionals/physician_gls/pdf/genetics_screening.pdf. Accessed Sept 19, 2016.
12. Beattie MS, Crawford B, Lin F, Vittinghoff E, Ziegler J. Uptake, time course, and predictors of risk-reducing surgeries in BRCA carriers. Genet Test Mol Biomarkers. 2009;13:51-56.
13. Metcalfe KA, Birenbaum-Carmeli D, Lubinski J, et al. International variation in rates of uptake of preventive options in BRCA1 and BRCA2 mutation carriers. Int J Cancer. 2008;122:2017-2022.
14. Metcalfe KA, Lubinski J, Ghadirian P, et al. Predictors of contralateral prophylactic mastectomy in women with a BRCA1 or BRCA2 mutation: the Hereditary Breast Cancer Clinical Study Group. J Clin Oncol. 2008;26:1093-1097.
15. Schwartz MD, Isaacs C, Graves KD, et al. Long-term outcomes of BRCA1/BRCA2 testing: risk reduction and surveillance. Cancer. 2012;118:510-517.
16. Garcia C, Wendt J, Lyon L, et al. Risk management options elected by women after testing positive for a BRCA mutation. Gynecol Oncol. 2014;132:428-433.
17. Watson M, Kash KM, Homewood J, Ebbs S, Murday V, Eeles R. Does genetic counseling have any impact on management of breast cancer risk? Genet Test. 2005;9:167-174.
18. Roukos DH, Briasoulis E. Individualized preventive and therapeutic management of hereditary breast ovarian cancer syndrome. Nat Clin Pract Oncol. 2007;4:578-590.
19. Narod SA, Offit K. Prevention and management of hereditary breast cancer. J Clin Oncol. 2005;23:1656-1663.
20. Drohan B, Roche CA, Cusack JC Jr, Hughes KS. Hereditary breast and ovarian cancer and other hereditary syndromes: using technology to identify carriers. Ann Surg Oncol. 2012;19:1732-1737.
21. Mai PL, Vadaparampil ST, Breen N, McNeel TS, Wideroff L, Graubard BI. Awareness of cancer susceptibility genetic testing: the 2000, 2005, and 2010 National Health Interview Surveys. Am J Prev Med. 2014;46:440-448.
22. Pagan JA, Su D, Li L, Armstrong K, Asch DA. Racial and ethnic disparities in awareness of genetic testing for cancer risk. Am J Prev Med. 2009;37:524-530.
23. Jones T, Lockhart JS, Mendelsohn-Victor KE, et al. Use of cancer genetics services in African-American young breast cancer survivors. Am J Prev Med. 2016;51:427-436.
24. Hall MJ, Reid JE, Burbidge LA, et al. BRCA1 and BRCA2 mutations in women of different ethnicities undergoing testing for hereditary breast-ovarian cancer. Cancer. 2009;115:2222-2233.
25. Bellcross CA, Kolor K, Goddard KA, Coates RJ, Reyes M, Khoury MJ. Awareness and utilization of BRCA1/2 testing among US primary care physicians. Am J Prev Med. 2011;40:61-66.
26. Bellcross CA, Leadbetter S, Alford SH, Peipins LA. Prevalence and healthcare actions of women in a large health system with a family history meeting the 2005 USPSTF recommendation for BRCA genetic counseling referral. Cancer Epidemiol Biomarkers Prev. 2013;22:728-735.
27. Trivers KF, Baldwin LM, Miller JW, et al. Reported referral for genetic counseling or BRCA1/2 testing among United States physicians: a vignette-based study. Cancer. 2011;117:5334-5343.
28. Wood ME, Kadlubek P, Pham TH, et al. Quality of cancer family history and referral for genetic counseling and testing among oncology practices: a pilot test of quality measures as part of the American Society of Clinical Oncology Quality Oncology Practice Initiative. J Clin Oncol. 2014;32:824-829.
29. Pal T, Rocchio E, Garcia A, Rivers D, Vadaparampil S. Recruitment of black women for a study of inherited breast cancer using a cancer registry-based approach. Genet Test Mol Biomarkers. 2011;15:69-77.
30. Bonner D, Pal T, Tallo C, Vadaparampil ST. The utility of a state-wide cancer registry in recruiting a clinically representative population-based sample of young black women diagnosed with early onset breast cancer. Paper presented at: Fifth Conference on the Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved; October 27–30, 2012; San Diego, CA.
31. Kinney AY, Simonsen SE, Baty BJ, et al. Risk reduction behaviors and provider communication following genetic counseling and BRCA1 mutation testing in an African American kindred. J Genet Couns. 2006;15:293-305.
32. Buchanan AH, Voils CI, Schildkraut JM, et al. Adherence to recommended risk management among unaffected women with a BRCA mutation [published online ahead of print June 6, 2016]. J Genet Couns. doi: 10.1007/s10897-016-9981-6.
33. Frank TS, Deffenbaugh AM, Reid JE, et al. Clinical characteristics of individuals with germline mutations in BRCA1 and BRCA2: analysis of 10,000 individuals. J Clin Oncol. 2002;20:1480-1490.
34. McCarthy AM, Bristol M, Domchek SM, et al. Health care segregation, physician recommendation, and racial disparities in BRCA1/2 testing among women with breast cancer. J Clin Oncol. 2016;34:2610-2618.
35. Hall MJ, Olopade OI. Disparities in genetic testing: thinking outside the BRCA box. J Clin Oncol. 2006;24:2197-2203.
36. Levy DE, Byfield SD, Comstock CB, et al. Underutilization of BRCA1/2 testing to guide breast cancer treatment: black and Hispanic women particularly at risk. Genet Med. 2011;13:349-355.
37. Sussner KM, Jandorf L, Thompson HS, Valdimarsdottir HB. Interest and beliefs about BRCA genetic counseling among at-risk Latinas in New York City. J Genet Couns. 2010;19:255-268.
38. Sussner KM, Jandorf L, Thompson HS, Valdimarsdottir HB. Barriers and facilitators to BRCA genetic counseling among at-risk Latinas in New York City. Psychooncology. 2013;22:1594-1604.
39. Sussner KM, Edwards T, Villagra C, et al. BRCA genetic counseling among at-risk Latinas in New York City: new beliefs shape new generation. J Genet Couns. 2015;24:134-148.
40. Gammon AD, Rothwell E, Simmons R, et al. Awareness and preferences regarding BRCA1/2 genetic counseling and testing among Latinas and non-Latina white women at increased risk for hereditary breast and ovarian cancer. J Genet Couns. 2011;20:625-638.
41. Adams I, Christopher J, Williams KP, Sheppard VB. What black women know and want to know about counseling and testing for BRCA1/2. J Cancer Educ. 2015;30:344-352.
42. Kolb B, Wallace AM, Hill D, Royce M. Disparities in cancer care among racial and ethnic minorities. Oncology (Williston Park). 2006;20:1256-1261; discussion 1261, 1265, 1268–1270.
43. Pal T, Vadaparampil ST. Genetic risk assessments in individuals at high risk for inherited breast cancer in the breast oncology care setting. Cancer Control. 2012;19:255-266.
44. US Census Bureau. America Speaks: A Demographic Profile of Foreign-Language Speakers for the United States: 2000. Report No. PHC-T-42. Washington, DC: US Census Bureau; 2010.
45. Armstrong K, Micco E, Carney A, Stopfer J, Putt M. Racial differences in the use of BRCA1/2 testing among women with a family history of breast or ovarian cancer. JAMA. 2005;293:1729-1736.
46. Anderson B, McLosky J, Wasilevich E, Lyon-Callo S, Duquette D, Copeland G. Barriers and facilitators for utilization of genetic counseling and risk assessment services in young female breast cancer survivors [serial online]. J Cancer Epidemiol 2012:298745, 2012.
47. Rosenberg SM, Ruddy KJ, Tamimi RM, et al. BRCA1 and BRCA2 mutation testing in young women with breast cancer. JAMA Oncol. 2016;2:730-736.
48. Jagsi R, Griffith KA, Kurian AW, et al. Concerns about cancer risk and experiences with genetic testing in a diverse population of patients with breast cancer. J Clin Oncol. 2015;33:1584-1591.
49. McCarthy AM, Bristol M, Fredricks T, et al. Are physician recommendations for BRCA1/2 testing in patients with breast cancer appropriate? A population-based study. Cancer. 2013;119:3596-3603.
50. Jolie A. My Medical Choice. Available at: http://www.nytimes.com/2013/05/14/opinion/my-medical-choice.html?_r=0. Accessed July 18, 2013.
51. Cho MK, Sankar P, Wolpe PR, Godmilow L. Commercialization of BRCA1/2 testing: practitioner awareness and use of a new genetic test. Am J Med Genet. 1999;83:157-163.
52. Nelson HD, Fu R, Goddard K, et al. Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer: Systematic Review to Update the US Preventive Services Task Force Recommendation. Report No. 12–05164-EF-1. Rockville, MD: Agency for Healthcare Research and Quality. US Preventive Services Task Force; 2013.
53. Prince AE. Prevention for those who can pay: insurance reimbursement of genetic-based preventive interventions in the liminal state between health and disease. J Law Biosci. 2015;2:365-395.